Cvfg LLC Acquires New Position in Phibro Animal Health Corporation $PAHC

Key Points

• Cvfg LLC disclosed a new stake in Phibro Animal Health, buying 53,560 shares valued at about $2.96 million in the first quarter.
• Several analysts have turned more cautious on PAHC recently, with multiple downgrades and Citigroup cutting its price target to $44; the stock now carries a Hold consensus rating.
• Phibro Animal Health reported quarterly results that beat expectations, with EPS of $0.76 and revenue of $383.54 million, and it also pays a quarterly dividend of $0.12 per share.

Cvfg LLC acquired a new position in shares of Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 53,560 shares of the company's stock, valued at approximately $2,962,000. Cvfg LLC owned 0.13% of Phibro Animal Health as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of PAHC. 1620 Investment Advisors Inc. grew its holdings in shares of Phibro Animal Health by 77.4% during the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company's stock valued at $25,000 after purchasing an additional 295 shares during the last quarter. Tudor Investment Corp ET AL lifted its holdings in shares of Phibro Animal Health by 3.4% in the 3rd quarter. Tudor Investment Corp ET AL now owns 10,184 shares of the company's stock worth $412,000 after purchasing an additional 338 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Phibro Animal Health by 2.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company's stock valued at $332,000 after purchasing an additional 363 shares during the period. Farther Finance Advisors LLC boosted its position in Phibro Animal Health by 113.2% during the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company's stock valued at $27,000 after purchasing an additional 386 shares during the period. Finally, Brooklyn Investment Group grew its stake in Phibro Animal Health by 8.7% during the 4th quarter. Brooklyn Investment Group now owns 6,757 shares of the company's stock worth $255,000 after buying an additional 538 shares during the last quarter. Institutional investors own 99.34% of the company's stock.

Analyst Ratings Changes

PAHC has been the topic of several analyst reports. Weiss Ratings lowered Phibro Animal Health from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Monday, June 15th. Wall Street Zen lowered shares of Phibro Animal Health from a "strong-buy" rating to a "buy" rating in a research report on Saturday, May 9th. Citigroup dropped their price objective on shares of Phibro Animal Health from $62.00 to $44.00 and set a "neutral" rating on the stock in a report on Thursday, May 14th. Finally, Zacks Research downgraded shares of Phibro Animal Health from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 21st. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Phibro Animal Health currently has a consensus rating of "Hold" and a consensus target price of $42.50.

Insiders Place Their Bets

In other news, CEO Jack Bendheim sold 4,528 shares of the firm's stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $48.49, for a total transaction of $219,562.72. Following the completion of the transaction, the chief executive officer owned 56,152 shares in the company, valued at approximately $2,722,810.48. This trade represents a 7.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 46,768 shares of company stock valued at $2,560,222. 50.13% of the stock is currently owned by corporate insiders.

Phibro Animal Health Stock Down 3.0%

PAHC opened at $33.12 on Wednesday. The stock's 50 day moving average price is $35.64 and its 200 day moving average price is $43.71. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.17 and a quick ratio of 1.26. The stock has a market cap of $1.34 billion, a P/E ratio of 14.21, a P/E/G ratio of 0.48 and a beta of 0.46. Phibro Animal Health Corporation has a 12 month low of $25.58 and a 12 month high of $60.08.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.04. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.The company had revenue of $383.54 million during the quarter, compared to analysts' expectations of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. As a group, research analysts predict that Phibro Animal Health Corporation will post 3.08 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, June 24th. Shareholders of record on Wednesday, June 3rd were issued a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date of this dividend was Wednesday, June 3rd. Phibro Animal Health's dividend payout ratio is presently 20.60%.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation NASDAQ: PAHC is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.

Want to see what other hedge funds are holding PAHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.